NPO "Microgen"

FSUE NPO Microgen of the Ministry of Health of Russia is a Russian manufacturer of immunobiological drugs. The "portfolio" of the enterprise includes 62 vital drugs, 13 vaccines of the National Calendar of Preventive Vaccinations and 10 vaccines against socially significant infectious diseases.

NPO Microgen is one of the three leaders in terms of sales among Russian pharmaceutical companies (according to 2012 data, DSM Group, Remedium, Pharmvestnik). As of August 2017, the company is an extensive network of state-owned enterprises, including 9 production sites, each of which is engaged in the development and release of certain categories or names of drugs. The enterprises of NPO Microgen are located in Perm, Ufa and Tomsk, Stavropol, Irkutsk, Nizhny Novgorod, Makhachkala, Moscow, Omsk and Belorechensk.

The company's development strategy involves fully meeting the need of the Russian market for high-quality domestic immunobiological drugs and modernizing assets by 2020. The company plans to update the means of production from its own profits without attracting government funding.

The total staff is more than 6,000 people.

The "portfolio" of the enterprise includes 62 drugs included in the list of vital drugs and 121 names of immunobiological drugs, including 13 vaccines of the National Calendar of Preventive Vaccinations and 10 vaccines against socially significant infectious diseases.

The history of the Company's branches: Perm NPO Biomed in Perm, Immunopreparat in Ufa and NPO Virion in Tomsk has more than 100 years of activity and is directly related to the origins of Russian immunological science.

History

2022: Ildar Mingazov received a deadline for the purchase of sick mice

In June 2022, the Chishminsky District Court (Republic of Bashkortostan) sentenced the former director of the Laboratory Animal Nursery (a branch of the Russian drug manufacturer NPO Microgen JSC), 62-year-old Ildar Mingazov, to a suspended sentence for abuse of office with serious consequences (clause "c" part 3 of article 286 of the Criminal Code of the Russian Federation). Read more here.

2021: Natsimbio became the 100% owner of NPO Microgen

On September 8, 2021, it was announced that Natsimbio became the 100% owner of NPO Microgen. Previously, this scientific and production organization belonged to the Federal Property Management Agency.

Natsimbio CEO Andrei Zagorski, commenting on the deal to join NPO Microgen to the holding, called it "an important step towards creating a strong player on the Russian pharmaceutical market capable of ensuring the independence of the Russian Federation in the production of strategically important biological drugs." Integration will give the company an additional impetus, which will allow the creation and production of drugs that meet all modern requirements, he added.

Natsimbio became the 100% owner of NPO Microgen

In order to develop NPO Microgen, Natsimbio Holding intends to increase production volumes in regional branches of the enterprise, create technological capacities and develop new drugs. A large-scale investment program will be implemented on the basis of Microgen, part of which will be the creation at the enterprise in Perm of the production of vaccines and blood plasma preparations.

By September 2021, NGO Microgen produces 20 different vaccines for the prevention of 15 infectious diseases, including the coronavirus COVID-19. Serums, blood products, allergens, probiotics and bacteriophages are also produced on the basis of the enterprise - a total of 250 types of drugs. Microgen accounts for more than 40% of the domestic market for vaccines and toxoids, about 20% of the market for albumins and immunoglobulins, 100% for medicinal preparations of bacteriophages and Russian allergens, the press service of Rostec reports (Natsimbio is part of this state corporation).

Natsimbio, according to its own data, supplies 90% of vaccines in Russia for tuberculosis, hepatitis B, measles, rubella, mumps, influenza, diphtheria, tetanus and pertussis.^[1]

2018: Phase two clinical trials of meningitis vaccine

In March 2018, NPO Microgen (part of the National Immunobiological Company of Rostec State Corporation) began the second phase of clinical studies of the first domestic polysaccharide meningococcal vaccine for the prevention of diseases caused by bacteria of the Neisseria meningitidis species of two serogroups A and C at once, including meningitis and meningococcemia.

As part of the second phase, Microgen will conduct clinical trials of the drug on volunteers for efficacy and safety. Preclinical studies with laboratory animals and the results of the first phase of clinical studies completed in the second quarter of 2017 confirmed the safety and high tolerability of the drug. The second phase of the tests is scheduled to be completed in the second quarter of 2018.

The work is carried out within the framework of the import substitution program, designed to reduce Russia's dependence on foreign suppliers in critical areas, including healthcare. According to its results, we expect to receive the first domestic polysaccharide meningococcal vaccine, which can replace imported drugs and be used within the framework of the national vaccination calendar, "said Oleg Yevtushenko, executive director of Rostec State Corporation.

To create a domestic polyvalent meningococcal vaccine, a scientific and production association introduced a controlled reactor method for culturing vaccine strains of meningococcal groups A and C, which makes it possible to automate and quickly scale the production volumes of the drug in the event of epidemics.

We set ourselves the task of developing an effective drug in a short time, since as of March 2018, domestic multivalent meningococcal vaccines of serotypes A and C are not produced in Russia, vaccines are represented only by foreign drugs. The results of preclinical research and current work make it possible to highly assess the prospects for the Russian vaccine, "said Kirill Gaidash, Director General of NPO Microgen .

According to the World Health Organization (WHO), the pathogen Neisseria meningitides is the leading cause of meningococcal meningitis. Serogroups A and C of the pathogen account for about 90% of all cases of the disease. Meningococcal disease often manifests as scattered, unrelated, cases or small outbreaks that can result in epidemics.

Notes